PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.55%
Negative revenue growth while TSM stands at 3.57%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
3.51%
Gross profit growth under 50% of TSM's 9.57%. Michael Burry would be concerned about a severe competitive disadvantage.
5.06%
EBIT growth 50-75% of TSM's 7.37%. Martin Whitman would suspect suboptimal resource allocation.
5.06%
Operating income growth at 50-75% of TSM's 7.37%. Martin Whitman would doubt the firm’s ability to compete efficiently.
16.13%
Net income growth above 1.5x TSM's 6.42%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.63%
EPS growth above 1.5x TSM's 2.28%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
10.00%
Diluted EPS growth above 1.5x TSM's 2.28%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.18%
Share reduction more than 1.5x TSM's 2.19%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.19%
Diluted share reduction more than 1.5x TSM's 2.28%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-47.14%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-76.13%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
386.85%
10Y revenue/share CAGR at 75-90% of TSM's 431.67%. Bill Ackman would press for new markets or product lines to narrow the gap.
416.09%
5Y revenue/share CAGR above 1.5x TSM's 161.22%. David Dodd would look for consistent product or market expansions fueling outperformance.
21.27%
3Y revenue/share CAGR under 50% of TSM's 83.44%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
1047.86%
OCF/share CAGR of 1047.86% while TSM is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
200.98%
OCF/share CAGR of 200.98% while TSM is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
6289.46%
3Y OCF/share CAGR above 1.5x TSM's 86.81%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
637.92%
Net income/share CAGR 1.25-1.5x TSM's 452.79%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
408.37%
Below 50% of TSM's 865.23%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
1184.03%
3Y net income/share CAGR above 1.5x TSM's 335.62%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
921.18%
Equity/share CAGR of 921.18% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
846.67%
Equity/share CAGR of 846.67% while TSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
30.11%
3Y equity/share CAGR at 50-75% of TSM's 54.08%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.23%
AR growth well above TSM's 6.42%. Michael Burry fears inflated revenue or higher default risk in the near future.
-2.21%
Inventory is declining while TSM stands at 18.75%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.70%
Asset growth at 50-75% of TSM's 9.30%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.45%
Positive BV/share change while TSM is negative. John Neff sees a clear edge over a competitor losing equity.
-100.00%
We’re deleveraging while TSM stands at 6.52%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.12%
Our R&D shrinks while TSM invests at 10.55%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
7.54%
SG&A declining or stable vs. TSM's 38.52%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.